<DOC>
	<DOCNO>NCT00845936</DOCNO>
	<brief_summary>Atypical antipsychotic ( AA ) broadly use treat variety psychiatric neurological disorder child adolescent . Weight gain common side effect drug . AA induce weight gain cause metabolic syndrome major health concern , well cancer significant psychological disorder . Weight gain may also lead low compliance AAs . A number study conduct order find way prevent , reduce reverse AA induce weight gain child adolescent , far commonly accepted treatment problem . Metformin antihyperglycemic drug , approve FDA treatment type 2 diabetes child old 10 year age . The drug usually cause hypoglycemia , even high dosage . Contraindications include renal impairment , hepatic disease , past history lactic acidosis ( cause ) , cardiac failure require pharmacological therapy , chronic hypoxic lung disease . The drug also discontinue temporarily prior administration intravenous contrast medium prior surgical procedure . The reported incidence lactic acidosis metformin treatment le 0.1 case per 1000 patient-years , mortality risk even low . Acute side effect metformin , occur 20 % patient , include diarrhea , abdominal discomfort , nausea , metallic taste , anorexia . These usually minimize increasing dosage drug slowly , indicate , take meal . Intestinal absorption vitamin B 12 folate often decrease chronic metformin therapy , calcium supplement reverse effect metformin vitamin B12 absorption . Three study study effect metformin weight gain secondary use AAs adult 3 study study effect metformin child adolescent . Most study prove drug efficient . No serious side effect demonstrate study . Objective- To assess effect metformin body weight child adolescent treat AAs . Setting- recruitment follow would take place pediatric ward outpatient clinic Ness- Tziona Mental Health Center . Participants- 30 adolescent age 12- 20 year old , treated AAs , overweight define 10 % expect accord age height . Importance Study 1 . Identify medication capable reduce prevent weight gain AA agent . 2 . Identify agent capable improve compliance due low side-effect profile AAs .</brief_summary>
	<brief_title>Metformin Weight Control Adolescents Taking Atypical Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1220 year old treat atypical antipsychotic weight gain 10 % expect age Overweight 10 % expect age height Physical condition require pharmacological treatment Changes drug type dosage 2 month trial , except 25 % change dosage</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Atypical antipsychotic</keyword>
	<keyword>Weight</keyword>
	<keyword>adolecsents</keyword>
	<keyword>pediatric</keyword>
	<keyword>Metformin</keyword>
</DOC>